The Marked Chart Wire · Health
Summit Therapeutics
Fda rejects Summit's Ivonescimab application citing survival data
The FDA reported that Summit Therapeutics' Ivonescimab application cannot be approved in its current form. The agency cited a lack of statistically significant overall survival improvement in the HARMONi study.
